Price Comparison
Mazdutide
fat loss
6 of 6 vendors
| Vendor | Price | 10mg cost | Updated | Actions |
|---|---|---|---|---|
| Alpha Peptides 8/10 COA ✓Ships: USCredit/debit card Verification & shipping8/10 COA ✓Ships: USCredit/debit card | $66.43 | $66.43Checked jul 31, 2026 | Jul 31, 2026 | Buy Mazdutide from Alpha Peptides |
| PeakForm Peptides 8/10 COA ✓Ships: USCredit/debit card Verification & shipping8/10 COA ✓Ships: USCredit/debit card | $70.0010mg package | $70.00Checked aug 1, 2026 | Aug 1, 2026 | Buy Mazdutide from PeakForm Peptides |
| Nationwide Peptides 6/10 COA ✓Ships: USCredit/debit card Verification & shipping6/10 COA ✓Ships: USCredit/debit card | $89.10 | $89.10Checked aug 5, 2026 | Aug 5, 2026 | Buy Mazdutide from Nationwide Peptides |
| Hydro Research 9/10 COA ✓Ships: USVisa · Mastercard Verification & shipping9/10 COA ✓Ships: USVisa · Mastercard | $76.50 | $153.00Checked jun 5, 2026 | Jun 5, 2026 | Buy Mazdutide from Hydro Research |
| Offline Peptides 7.5/10 COA ✓Ships: USCredit/debit card Verification & shipping7.5/10 COA ✓Ships: USCredit/debit card | $89.005mg package | $178.00Checked jul 28, 2026 | Jul 28, 2026 | Buy Mazdutide from Offline Peptides |
| Optima Supply 8.5/10 COA ✓Ships: USCredit/debit card Verification & shipping8.5/10 COA ✓Ships: USCredit/debit card | $93.50 | $187.00Checked aug 3, 2026 | Aug 3, 2026 | Buy Mazdutide from Optima Supply |
Research details
Mazdutide — research data
Overview
About Mazdutide
Mechanism of action
Dual GLP-1 receptor and glucagon receptor (GCGR) agonist; GLP-1 component suppresses appetite and improves glycemia; glucagon component increases energy expenditure, promotes lipolysis, and reduces hepatic fat; weekly injection.
Safety profile
Nausea, vomiting, diarrhea, decreased appetite; glucagon effects may include hyperglycemia at high doses; still in trials. · Phase III trials ongoing; GI side effects; dual agonist; promising efficacy and tolerability
Related pages
More on Mazdutide
Research
Studies & key findings
- Mazdutide (IBI362 / LY3305677) is a dual GLP-1 + glucagon receptor agonist — an oxyntomodulin analog — distinct from GLP-2T (GIP/GLP-1). The glucagon arm adds thermogenesis/energy expenditure on top of GLP-1 appetite suppression.
- Reported Phase 3 results (GLORY program, Innovent/Lilly, largely Chinese cohorts) describe up to ~20% weight loss at 9 mg over 60 weeks — but these figures are company/topline-stage and should be confirmed against the primary publications before being treated as established.